Physician profile
Jill D Hoffman
NPI 1477719672
$5,162.68
in general payments reported to CMS, 2019-2025
18 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $297 · 2023: $1,614 · 2024: $1,393 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600 · Education: $86.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,600.37 |
| Education | $86.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,384.09 | 2022-2025 | |
| Janssen Biotech, INC. | $882.85 | 2023-2025 | Tremfya, Stelara, Remicade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $469.36 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Gilead Sciences, INC. | $417.64 | 2023-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $215.87 | 2023-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $182.19 | 2024-2025 | |
| Ardelyx, INC. | $129.38 | 2023-2025 | Ibsrela |
| Abbott Laboratories | $110.60 | 2023-2025 | Freestyle Libre |
| Intercept Pharmaceuticals, INC. | $86.32 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $54.11 | 2025 | Iqirvo |
| Pfizer INC. | $53.00 | 2023-2025 | |
| Celltrion USA INC. | $48.12 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $37.66 | 2023 | Sutab, Suflave |
| Alnylam Pharmaceuticals INC. | $25.90 | 2022 | |
| Exact Sciences Corporation | $23.96 | 2024 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.93 | 2024 | Voquezna |
| Celgene Corporation | $15.46 | 2023 | Zeposia |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.